The Role of Angiotensin–(1-7) in Cancer
作者： Ana Cristina Simões e Silva , Walkyria O. Sampaio
DOI: 10.1007/978-3-030-22696-1_14
关键词: Metastasis 、 Cancer cell 、 Cancer research 、 Breast cancer 、 Angiogenesis 、 Cancer 、 Lung cancer 、 Bone marrow 、 Prostate cancer 、 Medicine
摘要: The rationale to investigate the role of angiotensin-(1-7) [Ang-(1-7)] in cancer relies on fact that heptapeptide inhibits growth several cell lines. first studies showed Ang-(1-7) accelerated hematopoietic recovery peripheral blood and bone marrow after chemotherapy lung through activation Mas receptor. In this chapter, we summarize different types cancer, especially lung, breast, prostate, hepatocellular cancers gliobalstoma multiforme (GBM). antitumor effect was due reduction angiogenesis, cancer-associated fibrosis, osteoclastogenesis, tumor-induced inflammation, metastasis as well inhibition proliferation. clinical trials, tolerated with limited toxic or quality-of-life side effects benefit patients solid tumors. Further trials are needed confirm safety, determine doses indications.
springer.com
sci-hub.st 参考文章(48)
Kathleen Rodgers, Shiquin Xiong, Gere S. diZerega, Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemotherapy and Pharmacology. ,vol. 51, pp. 97- 106 ,(2003) , 10.1007/S00280-002-0509-4
Tetsuya Mitsudomi, Hiroyuki Achiwa, Ken-ichi Kozaki, Toyoaki Hida, Hideki Muramatsu, Shigeo Nakamura, Yasushi Yatabe, Takahiko Sugiura, Makoto Ogawa, Takashi Takahashi, Increased Expression of Cyclooxygenase 2 Occurs Frequently in Human Lung Cancers, Specifically in Adenocarcinomas Cancer Research. ,vol. 58, pp. 3761- 3764 ,(1998)
Yanping Liu, Bin Li, Ximing Wang, Guishuang Li, Rui Shang, Jianmin Yang, Jiali Wang, Meng Zhang, Yuguo Chen, Yun Zhang, Cheng Zhang, Panpan Hao, Angiotensin-(1-7) Suppresses Hepatocellular Carcinoma Growth and Angiogenesis via Complex Interactions of Angiotensin II Type 1 Receptor, Angiotensin II Type 2 Receptor and Mas Receptor. Molecular Medicine. ,vol. 21, pp. 626- 636 ,(2015) , 10.2119/MOLMED.2015.00022
Debabrata Mukherjee, Eric J Topol, Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors. Arthritis Research & Therapy. ,vol. 5, pp. 8- 11 ,(2002) , 10.1186/AR609
W. J. Petty, A. A. Miller, T. P. McCoy, P. E. Gallagher, E. A. Tallant, F. M. Torti, Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone Clinical Cancer Research. ,vol. 15, pp. 7398- 7404 ,(2009) , 10.1158/1078-0432.CCR-09-1957
Kathleen E. Rodgers, Jamie Oliver, Gere S. diZerega, Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer Cancer Chemotherapy and Pharmacology. ,vol. 57, pp. 559- 568 ,(2006) , 10.1007/S00280-005-0078-4
Kathleen Rodgers, Shiquin Xiong, Gere diZerega, Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemotherapy and Pharmacology. ,vol. 49, pp. 403- 411 ,(2002) , 10.1007/S00280-002-0434-6
Bhavani Krishnan, Frank M. Torti, Patricia E. Gallagher, E. Ann Tallant, Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. The Prostate. ,vol. 73, pp. 60- 70 ,(2013) , 10.1002/PROS.22540
Huyen Pham, Benjamin M. Schwartz, James E. Delmore, Eddie Reed, Scott Cruickshank, Leanne Drummond, Kathleen E. Rodgers, Kainoa J. Peterson, Gere S. diZerega, Pharmacodynamic stimulation of thrombogenesis by angiotensin (1–7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy Cancer Chemotherapy and Pharmacology. ,vol. 71, pp. 965- 972 ,(2013) , 10.1007/S00280-013-2089-X
LaTronya T. McCollum, Patricia E. Gallagher, E. Ann Tallant, Angiotensin-(1–7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts Peptides. ,vol. 34, pp. 380- 388 ,(2012) , 10.1016/J.PEPTIDES.2012.01.020